Holekamp NM, et al. - Authors ascertained monitoring and treatment patterns, and vision outcomes in real-world patients initiating anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular oedema (DME). Findings suggested that less frequent monitoring and intravitreal injections in DME patients receiving anti-VEGF therapy in clinical practice was seen. Compared to patients in landmark clinical trials, these patients achieved inferior vision outcomes. Change in corrected visual acuity was seen to be similar in eyes receiving adjunctive laser compared to non–laser-treated eye during the first 6 months.